NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Jenburkt Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 10.35 %, QoQ Up 8.92 %

June 25, 2024June 25, 2024| adminadmin| 0 Comments| 2:00 pm
Image is loading
Categories:

Share the post "Jenburkt Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 10.35 %, QoQ Up 8.92 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 10.35 % in the past year, substantial increase in net sales/revenue by 8.92 %.
  • Income over the Year and quarter: There has been decline in other income over the past year which is -4.8 %, Marginal decrease of -11.19% in other income during this quarter.
  • Profit over the Year and quarter: Significant improvement in profitability for Jenburkt Pharmaceuticals Ltd.. Notable increase of 24.05 % in net profit Year to Year, Jenburkt Pharmaceuticals Ltd.’s profitability increased by 45.85 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 28.30 % Year to Year. EPS increased by 45.8 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Jenburkt Pharmaceuticals Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 35.199 Cr Rs. 35.66 Cr Rs. 38.842 Cr + 8.92 % + 10.35 %
Expenses Rs. 27.71 Cr Rs. 28.47 Cr Rs. 28.99 Cr + 1.83 % + 4.62 %
Operating Profit Rs. 7.49 Cr Rs. 7.19 Cr Rs. 9.85 Cr + 37 % + 31.51 %
OPM % 21.28 % 20.16 % 25.36 % + 5.2 % + 4.08 %
Other Income Rs. 1.25 Cr Rs. 1.34 Cr Rs. 1.19 Cr -11.19 % -4.8 %
Interest Rs. 0.08 Cr Rs. 0.07 Cr Rs. 0.06 Cr -14.29 % -25 %
Depreciation Rs. 0.59 Cr Rs. 0.63 Cr Rs. 0.62 Cr -1.59 % + 5.08 %
Profit before tax Rs. 8.07 Cr Rs. 7.83 Cr Rs. 10.36 Cr + 32.31 % + 28.38 %
Tax % 21.32 % 31.07 % 23.96 % -7.11 % + 2.64 %
Net Profit Rs. 6.35 Cr Rs. 5.4 Cr Rs. 7.88 Cr + 45.93 % + 24.09 %
EPS in Rs Rs. 13.92 Rs. 12.25 Rs. 17.86 + 45.8 % + 28.3 %


Today, we’re looking at Jenburkt Pharmaceuticals Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 10.35 %. However, it did see a marginal increase of 8.92 % from the previous quarter. Expenses ticked up slightly by 1.83 % quarter-on-quarter, aligning with the annual rise of 4.62 %. Operating profit, while up 31.51 % compared to last year, faced a quarter-on-quarter increase of 37 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.08 %, but an expansion of 5.2 % sequentially. Other income fell by -11.19 % compared to the last quarter, despite an annual decline of -4.8 %. Interest expenses dropped significantly by -14.29 % from the previous quarter, yet the year-over-year decrease remains at a moderate -25 %. Depreciation costs fell by -1.59 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 5.08 %. Profit before tax grew annually by 28.38 % but saw an increase from the preceding quarter by 32.31 %.
Tax expenses as a percentage of profits increased slightly by 2.64 % compared to last year, with a more notable quarter-on-quarter decrease of -7.11 %. Net profit rose by 24.09 % year-on-year but experienced a 45.93 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 28.3 % but a quarterly rise of 45.8 %. In summary, Jenburkt Pharmaceuticals Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 35.199 Cr Rs. 35.66 Cr Rs. 38.842 Cr + 8.92 % + 10.35 %
Expenses Rs. 27.71 Cr Rs. 28.47 Cr Rs. 28.99 Cr + 1.83 % + 4.62 %
Operating Profit Rs. 7.49 Cr Rs. 7.19 Cr Rs. 9.85 Cr + 37 % + 31.51 %
Net Profit Rs. 6.35 Cr Rs. 5.4 Cr Rs. 7.88 Cr + 45.93 % + 24.09 %
EPS in Rs Rs. 13.92 Rs. 12.25 Rs. 17.86 + 45.8 % + 28.3 %


In reviewing Jenburkt Pharmaceuticals Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.35 % year-on-year growth, however, there was a minor increase of 8.92 % from the previous quarter. Expenses rose by 4.62 % compared to the previous year, with a 1.83 % increase quarter-on-quarter. Operating Profit surged by 31.51 % annually, and saw a 37 % increase from the last quarter.
Net Profit showed yearly increase of 24.09 %, and experienced a 45.93 % increase from the previous quarter. Earnings Per Share (EPS) rose by 28.3 % annually, however rose by 45.8 % compared to the last quarter. In essence, while Jenburkt Pharmaceuticals Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Jenburkt Pharmaceuticals “]

Related Post